![7支气管哮喘-双语-课件_第1页](http://file4.renrendoc.com/view/e1b2d5eaa6f49611927d7de35544c866/e1b2d5eaa6f49611927d7de35544c8661.gif)
![7支气管哮喘-双语-课件_第2页](http://file4.renrendoc.com/view/e1b2d5eaa6f49611927d7de35544c866/e1b2d5eaa6f49611927d7de35544c8662.gif)
![7支气管哮喘-双语-课件_第3页](http://file4.renrendoc.com/view/e1b2d5eaa6f49611927d7de35544c866/e1b2d5eaa6f49611927d7de35544c8663.gif)
![7支气管哮喘-双语-课件_第4页](http://file4.renrendoc.com/view/e1b2d5eaa6f49611927d7de35544c866/e1b2d5eaa6f49611927d7de35544c8664.gif)
![7支气管哮喘-双语-课件_第5页](http://file4.renrendoc.com/view/e1b2d5eaa6f49611927d7de35544c866/e1b2d5eaa6f49611927d7de35544c8665.gif)
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
Asthma
ZhongminQiuDepartmentofRespiratoryMedicineTongjiHospitalofTongjiUniversityAsthma1WhatIsAsthma?
Asthmaisadiseasethatcharacterizedby:AirwayobstructionthatisreversibleeitherspontaneouslyorwithtreatmentchronicairwayinflammationIncreasedairwayresponsivenesstoavarietyofstimuliInflammationcausesrecurrentepisodesofwheezing,breathlessness,chesttightnessandcoughing,particularlyatnightorearlymorning
WhatIsAsthma?Asthmaisadi2
Epidemiology17-20millionAmericans(6-10%prevalence)1%estimatedprevalenceinmainlandofChina10millionmedicalvisits2millionemergencyvisits0.5millionhospitalization5000deathsannuallyMajorcauseofschoolandworkabsenceAtleast12billionperyear
Increasingburdenforyears Epidemiology17-20million3ImpactOfAsthmaOnPatients
Psychosocial:Poorself-esteemAnxietyaboutasthmaFearofbecomingillatout-doorAnxietyaboutexerciseFearofbeingdifferent
ImpactOfAsthmaOnPatients4DidYouKnow..
Asthmakillspeopleequallyregardlessofseveritylevel1/3ofdeathsareinthosewithmildasthma1/3ofdeathsareinthosewithmoderateasthma1/3ofdeathsareinthosewithsevereasthmaDidYouKnow..Asthmakills5WhatCausesAsthma?Asthmamaybecausedbygenetic,immuneand/orenvironmentalfactors,andisoftenassociatedwitheczemaandallergiesWedonotunderstandallofthecausesofasthmaoritsincreasingprevalenceItboilsdownto“Wejustdon’treallyknowforsure”WhatCausesAsthma?Asthmamay6WhatCausesAsthmaOfthe17millionasthmasufferersintheUS,10Million(approx.60%)haveallergicasthma.3millionofthosearechildrenExposuretocertainallergenstriggerasthmasymptomstobeginExposuretocertainirritantscanalsosetanasthmaepisodeinmotionWhatCausesAsthmaOfthe17m7TriggersandIrritantsTriggersandIrritants8CommonAllergens(Triggers) SeasonalPollensAnimaldandersaliva/urineDustMitesCockroaches/Mice/RatdroppingsandurineMoldSomemedicationsSomeFoods
CommonAllergens(Triggers) S9CommonIrritants(Triggers)ExerciseColdAirChalkDustViral/upperrespiratoryinfectionsAirpollutionTobaccosmokeorsecondhandsmokeChemicalirritantsandstrongsmellsStrongemotionalfeelingsDieselfumesCleaningsuppliesCommonIrritants(Triggers)Exe10AirwayHyperresponsivenessPlasmaleakageMucushypersecretionInflammatorycellrecruitmentandactivationNeuralactivationVirus-infectedepitheliumRV-InducedAirwayInflammationAirwayPlasmaMucusInflammatory11VirusescauseasthmaexacerbationsRVscause~60%ofvirus-inducedexacerbationsofasthmaRVsdirectlyinfectthebronchialairwaysTheresponsetoviralinfectionisshapedbythehost’santiviralresponseRV-InducedAsthmaVirusescauseasthmaexacerbat12Nakano,Y.etal.Chest2002;122:271S-a-275S-aPathophysiologicschemaforthedevelopmentofasthmaNakano,Y.etal.Chest2002;113
TheAllergicReactionTheAllergicReaction14TheAsthmaCascadeTheAsthmaCascade157支气管哮喘-双语-课件16MediatorPhasesEarly-phasereactioncausedbymediatorrelease,usuallypeakswithinanhourafterinitialexposuretotheallergen.Threetofourhoursafteranacuteasthmaepisode,a"late-phasereaction"mayoccurandmaylastupto24hoursMediatorPhasesEarly-phaserea17TheEndResultsOfTheCascade LocalizedmucosaledemainthewallsofthesmallbronchiolesSecretionofthickmucusintothebronchiolarlumens(Clogsandnarrowstheairways)SpasticcontractionofbronchiolarsmoothmuscleTheEndResultsOfTheCascade18NormalBronchioleInflamedBronchiole
withMucus NormalBronchioleInflamed19AirwayObstructionCopyright3MPharmaceuticals2004AirwayObstructionCopyright3M207支气管哮喘-双语-课件21RemodelingPhasesAirwaywallthickening.SubepithelialfibrosisSmoothmusclehyperplasiaandhypertrophyMyofibroblasthyperplasiaMucusmetaplasiaRemodelingPhasesAirwaywallt22Vignola,A.M.etal.Chest2003;123:417S-a-422S-aIncreasedthicknessofthebasementmembrane(arrow),andenhancedandabnormaldepositionoffibronectin,whichisidentifiedbyimmunohistochemistryusingaspecificmonoclonalantibody(dashedarrow),inthebronchialsubmucosaVignola,A.M.etal.Chest2023Increasedthicknessofthebasementmembrane,andenhancedandabnormaldepositionofcollageninthebronchialsubmucosaIncreasedthicknessofthebas24ALotGoingOnBeneathTheSurfaceAirwayinflammationAirflowobstructionBronchialhyperresponsiveness
SymptomsALotGoingOnBeneathTheSur25CommonSymptomsOfAsthmaFrequentcough,especiallyatnightShortnessofbreathorrapidbreathingChesttightnessChestpainWheezingFatigueCommonSymptomsOfAsthmaFrequ26Early
SignsOfAnAsthma“Episode”MildcoughDropinPeakFlowreadingItchy,wateryorglassyeyesItchy,scratchyorsorethroatRunnynoseStomachacheHeadacheSneezingCongestionRestlessnessDarkcirclesundereyesIrritabilityEarlySignsOfAnAsthma“Epis27MeasuresOfAssessment
AndMonitoringTwoAspects:InitialassessmentanddiagnosisofasthmaPeriodicassessmentandmonitoringMeasuresOfAssessment
AndMo28InitialAssessment&
DiagnosisofAsthmaDeterminesThat:PatienthasahistoryorpresenceofepisodicsymptomsofairflowobstructionAirflowobstructionisatleastpartiallyreversibleAlternativediagnosesareexcludedInitialAssessment&
Diagnosi29
MethodsforEstablishing
DiagnosisDetailedmedicalhistoryPhysicalexam:wheezeandrhonchus(rhonchi)SpirometrytodemonstratereversibilityMethodsforEstablishing
Dia30Diagnosisofasthma
Objectivemeasurements>20%diurnalvariationon3daysin
aweekfor2weeksonPEFdiaryorFEV1
15%(and200ml)increaseaftershortactingß2agonistorsteroidtabletsorFEV115%decreaseafter6minutesofrunningexercisehistamineormethacholinechallengeindifficultcasesSymptoms(episodic/variable)wheezeshortnessofbreathchesttightnesscoughSignsnone(common)wheeze–diffuse,bilateral,expiratory(inspiratory)tachypneaHelpfuladditionalinformationpersonal/familyhistoryofasthmaoratopyhistoryofworseningafteraspirin/NSAID,
blockeruserecognisedtriggers–pollens,dust,animals,exercise,viralinfections,chemicals,irritantspatternandseverityofsymptomsandexacerbationsConsiderthediagnosisofasthmainpatientswithsomeorallofthesefeaturesDiagnosisofasthma
Objective31
AsthmaLungAssessment
Spirometry
SpirometryisGoldstandardtoassistinasthmadiagnosisPerformedbeforeandafterbronchodilatordosetolookforairwayobstruction
reversibilityCanalsobedonewithhistamineormethylcholinechallenge,oranexercisechallengeinthecaseofexercise-inducedasthma
AsthmaLungAssessmentSpirom32
IsAirflowObstructionAtLeastPartiallyReversible?Use
spirometrytoestablishairflowobstructionFEV1<80%ofpredictedFEV1/FVC<70%UsespirometrytoestablishreversibilityFEV1increases>15%andatleast200mLafterusingashort-actinginhaledbeta2-agonistIsAirflowObstructionAtLea33PeakExpiratoryFlowVariability
AnanotherwaytoevaluateairwayobstructionThereisthedifferencebetweenthemorningandeveningPEFreadingsPEFreadingstendtobehigherintheeveningthaninthemorningPeakExpiratoryFlowVariabili34PeakFlowMetersPeakFlowMeters35
Differentialdiagnosisof
asthma
SomeofsymptomsofasthmaaresharedwithdiseasesofothersystemsNumerousrelativelycommonlungdiseasesNeedtodifferentiatefrominfectionsandrestrictivelung
disorders,andbetweenlocalandgeneralisedobstructionDifferentialdiagnosesinclude:COPDcardiacdiseaselaryngeal,trachealorlungtumourbronchiectasisforeignbodyinterstitiallungdiseasepulmonaryemboliaspirationvocalcorddysfunctionhyperventilationDifferentialdiagnosisof
ast36AsthmaSeverityLevelsMildIntermittentMildPersistentModeratePersistentSeverePersistentAsthmaSeverityLevelsMildIn37AsthmaSeverityLevelsBySymptomsMildIntermittent-Sx<2days/week Sx<2nights/monthMildPersistent-Sx>2x/weekbut<1x/day Sx>2nights/monthModeratePersistent-Sxeveryday Sx>1night/weekSeverePersistent- ContinualdaytimeSx FrequentSxatnight
AsthmaSeverityLevelsBySymp38MildIntermittentSymptoms£2days/weekwithnighttimesymptoms£2nights/monthAsymptomaticwithnormalpeakflowsbetweenexacerbationsExacerbationsarebrief(hourstoafewdays)PeakFlows³80%predictedwithvariability<20%MildIntermittentSymptoms£239MildPersistentSymptoms>2days/weekbut<1x/daywithnighttimesymptomsgreaterthan2nights/monthExacerbationsmayaffectactivityPeakflow³80%predictedwithvariabilityof<20-30%MildPersistentSymptoms>2da40ModeratePersistentChildislikelytohavedailysymptomsanduserelieverdailyChildiswakingupatleastonceaweekduetoasthmasymptomsPeakflows60-80%ofpredictedwithvariabilityof>30%ActivityisaffectedandexacerbationsmaylastdaysModeratePersistentChildisli41SeverePersistentContinualdaytimesymptomswithfrequentnighttimesymptomsVerylimitedphysicalactivityFrequentexacerbationsPeakflows£60%ofpredictedandvariabilityofmorethan30%TreatmentinvolvesacombinationofmanydrugtherapiesSeverePersistentContinualday42GoalsOfAsthmaTherapyPreventchronicandtroublesomesymptomsMaintain“normal”pulmonaryfunctionMaintainnormalactivitylevels-includingexerciseandotherphysicalactivityMinimizetheneedforemergencyroom/urgentcarevisitsorhospitalizationsGoalsOfAsthmaTherapyPrevent43
GoalsOfAsthmaTherapy
Continued…PreventrecurrentexacerbationsofsymptomsProvideoptimalpharmacotherapywithminimalornoadverseeffectsSatisfythepatient’sandthefamily’sgoalsforasthmacareGoalsOfAsthmaTherapy44
StepwiseApproachTo Asthma TherapyOutcome:BestPossibleResultsReliever:InhaledbetaagonistprnReliever:InhaledbetaagonistprnReliever:InhaledbetaagonistprnReliever:InhaledbetaagonistprnController:OnedailymedicationPossiblyaddlongactingbronchodilatorAnti-leukotrienesController:DailyinhaledcorticosteroidDailylongactingbronchodilatorAnti-leukotrieneController:DailyinhaledcorticosteroidDailylongactingbronchodilatorDaily/alternatedayoralcorticosteroidWhencontrolled,reducetherapyMonitorPEF:≥80%PEF:≥80%PEF:<60%STEP1:IntermittentSTEP2:MildPersistentSTEP3:ModeratePersistentSTEP4:SeverePersistentStepdownOutcome:ControlofAsthmaPEF:60-80% StepwiseApproachToOutcome:45BronchodilatorsRelaxingbronchialsmoothmuscletoopenuptheairway.Anti-inflammatoryagentsInhibitingthedevelopmentofairwayinflammationandstoppingongoinginflammation.Incombination,treatandpreventreversibleairwayobstructionandairwayhyperresponsiveness,relievethesymptomanddecreasetheexacerbation.CommonDrugsforAsthmaBronchodilatorsCommonDrugsfo46Long-termcontrolmedication(Controller)CorticosteriodsCromolyn/nedocromilLongactingb2agonists(LABA)LeukotrienemodifierQuickreliefmedication(Rescuer)Short-actingb2agonistsTheophyllineAnticholinergicsSystemicCorticosteriodsCommonDrugsforAsthmaLong-termcontrolmedication(477支气管哮喘-双语-课件48Stepwisemanagementof
asthmainadultsStep1:MildintermittentasthmaInhaledshortactingß2agonistasrequiredStepwisemanagementof
asthma49Stepwisemanagementof
asthmainadultsStep1:MildintermittentasthmaStep2:RegularpreventertherapyAddinhaledsteroid200-800mcg/day*400mcgisanappropriatestartingdoseformanypatientsStartatdoseofinhaledsteroidappropriatetoseverityofdisease.*BDPorequivalentStepwisemanagementof
asthma50Stepwisemanagementof
asthmainadultsStep1:MildintermittentasthmaStep3:Add-ontherapys1.Addinhaledlong-actingß2agonist(LABA)2.Assesscontrolofasthma:good
responsetoLABA–continueLABAbenefitfromLABAbutcontrolstillinadequate–continueLABAandincreaseinhaledsteroiddoseto800mcg/day*(ifnotalreadyonthisdose)noresponsetoLABA–stopLABAandincreaseinhaledsteroidto
800mcg/day*.Ifcontrolstillinadequate,institutetrialofothertherapies
(e.g.leukotrienereceptorantagonistorSRtheophylline)Step2:RegularpreventertherapyStartatdoseofinhaledsteroidappropriatetoseverityofdisease.*BDPorequivalentStepwisemanagementof
asthma51Stepwisemanagementof
asthmainadultsStep1:MildintermittentasthmaStep2:RegularpreventertherapyStartatdoseofinhaledsteroidappropriatetoseverityofdisease.*BDPorequivalentStep3:Add-ontherapyStep4:PersistentpoorcontrolConsidertrialsof:increasinginhaledsteroidupto2000mcg/day*additionoffourthdrug(e.g.leukotrienereceptorantagonist,SRtheophylline,ß2agonisttablet)Stepwisemanagementof
asthma52Stepwisemanagementof
asthmainadultsStep1:MildintermittentasthmaStep2:RegularpreventertherapyStartatdoseofinhaledsteroidappropriatetoseverityofdisease.*BDPorequivalentStep3:Add-ontherapyStep4:PersistentpoorcontrolStep5:ContinuousorfrequentuseoforalsteroidsUsedailysteroidtabletinlowestdoseprovidingadequatecontrolMaintainhighdoseinhaledsteroidat2000mcg/day*ConsiderothertreatmentstominimisetheuseofsteroidtabletsReferpatientforspecialistcareStepwisemanagementof
asthma53Stepwisemanagementof
asthmainadultsStep1:MildintermittentasthmaStep5:ContinuousorfrequentuseoforalsteroidsStep4:PersistentpoorcontrolStep3:Add-ontherapyStep2:RegularpreventertherapyStepwisemanagementof
asthma54OxygentherapyandmechanicalventilationShort-actingb2agonistsAminophyllineAnticholinergicsCorticosteriods
ManagementforAcuteExacerbation
ofAsthmaOxygentherapyandmechanical55SameasacuteexacerbationofasthmaFluidinfusionModificationofacidosisAntibioticsMaintenanceofelectrolytebalanceResolutionofcomplications
ManagementforStatusAsthmaticsSameasacuteexacerbationof56Asthma
ZhongminQiuDepartmentofRespiratoryMedicineTongjiHospitalofTongjiUniversityAsthma57WhatIsAsthma?
Asthmaisadiseasethatcharacterizedby:AirwayobstructionthatisreversibleeitherspontaneouslyorwithtreatmentchronicairwayinflammationIncreasedairwayresponsivenesstoavarietyofstimuliInflammationcausesrecurrentepisodesofwheezing,breathlessness,chesttightnessandcoughing,particularlyatnightorearlymorning
WhatIsAsthma?Asthmaisadi58
Epidemiology17-20millionAmericans(6-10%prevalence)1%estimatedprevalenceinmainlandofChina10millionmedicalvisits2millionemergencyvisits0.5millionhospitalization5000deathsannuallyMajorcauseofschoolandworkabsenceAtleast12billionperyear
Increasingburdenforyears Epidemiology17-20million59ImpactOfAsthmaOnPatients
Psychosocial:Poorself-esteemAnxietyaboutasthmaFearofbecomingillatout-doorAnxietyaboutexerciseFearofbeingdifferent
ImpactOfAsthmaOnPatients60DidYouKnow..
Asthmakillspeopleequallyregardlessofseveritylevel1/3ofdeathsareinthosewithmildasthma1/3ofdeathsareinthosewithmoderateasthma1/3ofdeathsareinthosewithsevereasthmaDidYouKnow..Asthmakills61WhatCausesAsthma?Asthmamaybecausedbygenetic,immuneand/orenvironmentalfactors,andisoftenassociatedwitheczemaandallergiesWedonotunderstandallofthecausesofasthmaoritsincreasingprevalenceItboilsdownto“Wejustdon’treallyknowforsure”WhatCausesAsthma?Asthmamay62WhatCausesAsthmaOfthe17millionasthmasufferersintheUS,10Million(approx.60%)haveallergicasthma.3millionofthosearechildrenExposuretocertainallergenstriggerasthmasymptomstobeginExposuretocertainirritantscanalsosetanasthmaepisodeinmotionWhatCausesAsthmaOfthe17m63TriggersandIrritantsTriggersandIrritants64CommonAllergens(Triggers) SeasonalPollensAnimaldandersaliva/urineDustMitesCockroaches/Mice/RatdroppingsandurineMoldSomemedicationsSomeFoods
CommonAllergens(Triggers) S65CommonIrritants(Triggers)ExerciseColdAirChalkDustViral/upperrespiratoryinfectionsAirpollutionTobaccosmokeorsecondhandsmokeChemicalirritantsandstrongsmellsStrongemotionalfeelingsDieselfumesCleaningsuppliesCommonIrritants(Triggers)Exe66AirwayHyperresponsivenessPlasmaleakageMucushypersecretionInflammatorycellrecruitmentandactivationNeuralactivationVirus-infectedepitheliumRV-InducedAirwayInflammationAirwayPlasmaMucusInflammatory67VirusescauseasthmaexacerbationsRVscause~60%ofvirus-inducedexacerbationsofasthmaRVsdirectlyinfectthebronchialairwaysTheresponsetoviralinfectionisshapedbythehost’santiviralresponseRV-InducedAsthmaVirusescauseasthmaexacerbat68Nakano,Y.etal.Chest2002;122:271S-a-275S-aPathophysiologicschemaforthedevelopmentofasthmaNakano,Y.etal.Chest2002;169
TheAllergicReactionTheAllergicReaction70TheAsthmaCascadeTheAsthmaCascade717支气管哮喘-双语-课件72MediatorPhasesEarly-phasereactioncausedbymediatorrelease,usuallypeakswithinanhourafterinitialexposuretotheallergen.Threetofourhoursafteranacuteasthmaepisode,a"late-phasereaction"mayoccurandmaylastupto24hoursMediatorPhasesEarly-phaserea73TheEndResultsOfTheCascade LocalizedmucosaledemainthewallsofthesmallbronchiolesSecretionofthickmucusintothebronchiolarlumens(Clogsandnarrowstheairways)SpasticcontractionofbronchiolarsmoothmuscleTheEndResultsOfTheCascade74NormalBronchioleInflamedBronchiole
withMucus NormalBronchioleInflamed75AirwayObstructionCopyright3MPharmaceuticals2004AirwayObstructionCopyright3M767支气管哮喘-双语-课件77RemodelingPhasesAirwaywallthickening.SubepithelialfibrosisSmoothmusclehyperplasiaandhypertrophyMyofibroblasthyperplasiaMucusmetaplasiaRemodelingPhasesAirwaywallt78Vignola,A.M.etal.Chest2003;123:417S-a-422S-aIncreasedthicknessofthebasementmembrane(arrow),andenhancedandabnormaldepositionoffibronectin,whichisidentifiedbyimmunohistochemistryusingaspecificmonoclonalantibody(dashedarrow),inthebronchialsubmucosaVignola,A.M.etal.Chest2079Increasedthicknessofthebasementmembrane,andenhancedandabnormaldepositionofcollageninthebronchialsubmucosaIncreasedthicknessofthebas80ALotGoingOnBeneathTheSurfaceAirwayinflammationAirflowobstructionBronchialhyperresponsiveness
SymptomsALotGoingOnBeneathTheSur81CommonSymptomsOfAsthmaFrequentcough,especiallyatnightShortnessofbreathorrapidbreathingChesttightnessChestpainWheezingFatigueCommonSymptomsOfAsthmaFrequ82Early
SignsOfAnAsthma“Episode”MildcoughDropinPeakFlowreadingItchy,wateryorglassyeyesItchy,scratchyorsorethroatRunnynoseStomachacheHeadacheSneezingCongestionRestlessnessDarkcirclesundereyesIrritabilityEarlySignsOfAnAsthma“Epis83MeasuresOfAssessment
AndMonitoringTwoAspects:InitialassessmentanddiagnosisofasthmaPeriodicassessmentandmonitoringMeasuresOfAssessment
AndMo84InitialAssessment&
DiagnosisofAsthmaDeterminesThat:PatienthasahistoryorpresenceofepisodicsymptomsofairflowobstructionAirflowobstructionisatleastpartiallyreversibleAlternativediagnosesareexcludedInitialAssessment&
Diagnosi85
MethodsforEstablishing
DiagnosisDetailedmedicalhistoryPhysicalexam:wheezeandrhonchus(rhonchi)SpirometrytodemonstratereversibilityMethodsforEstablishing
Dia86Diagnosisofasthma
Objectivemeasurements>20%diurnalvariationon3daysin
aweekfor2weeksonPEFdiaryorFEV1
15%(and200ml)increaseaftershortactingß2agonistorsteroidtabletsorFEV115%decreaseafter6minutesofrunningexercisehistamineormethacholinechallengeindifficultcasesSymptoms(episodic/variable)wheezeshortnessofbreathchesttightnesscoughSignsnone(common)wheeze–diffuse,bilateral,expiratory(inspiratory)tachypneaHelpfuladditionalinformationpersonal/familyhistoryofasthmaoratopyhistoryofworseningafteraspirin/NSAID,
blockeruserecognisedtriggers–pollens,dust,animals,exercise,viralinfections,chemicals,irritantspatternandseverityofsymptomsandexacerbationsConsiderthediagnosisofasthmainpatientswithsomeorallofthesefeaturesDiagnosisofasthma
Objective87
AsthmaLungAssessment
Spirometry
SpirometryisGoldstandardtoassistinasthmadiagnosisPerformedbeforeandafterbronchodilatordosetolookforairwayobstruction
reversibilityCanalsobedonewithhistamineormethylcholinechallenge,oranexercisechallengeinthecaseofexercise-inducedasthma
AsthmaLungAssessmentSpirom88
IsAirflowObstructionAtLeastPartiallyReversible?Use
spirometrytoestablishairflowobstructionFEV1<80%ofpredictedFEV1/FVC<70%UsespirometrytoestablishreversibilityFEV1increases>15%andatleast200mLafterusingashort-actinginhaledbeta2-agonistIsAirflowObstructionAtLea89PeakExpiratoryFlowVariability
AnanotherwaytoevaluateairwayobstructionThereisthedifferencebetweenthemorningandeveningPEFreadingsPEFreadingstendtobehigherintheeveningthaninthemorningPeakExpiratoryFlowVariabili90PeakFlowMetersPeakFlowMeters91
Differentialdiagnosisof
asthma
SomeofsymptomsofasthmaaresharedwithdiseasesofothersystemsNumerousrelativelycommonlungdiseasesNeedtodifferentiatefrominfectionsandrestrictivelung
disorders,andbetweenlocalandgeneralisedobstructionDifferentialdiagnosesinclude:COPDcardiacdiseaselaryngeal,trachealorlungtumourbronchiectasisforeignbodyinterstitiallungdiseasepulmonaryemboliaspirationvocalcorddysfunctionhyperventilationDifferentialdiagnosisof
ast92AsthmaSeverityLevelsMildIntermittentMildPersistentModeratePersistentSeverePersistentAsthmaSeverityLevelsMildIn93AsthmaSeverityLevelsBySymptomsMildIntermittent-Sx<2days/week Sx<2nights/monthMildPersistent-Sx>2x/weekbut<1x/day Sx>2nights/monthModeratePersistent-Sxeveryday Sx>1night/weekSeverePersistent- ContinualdaytimeSx FrequentSxatnight
AsthmaSeverityLevelsBySymp94MildIntermittentSymptoms£2days/weekwithnighttimesymptoms£2nights/monthAsymptomaticwithnormalpeakflowsbetweenexacerbationsExacerbationsarebrief(hourstoafewdays)PeakFlows³80%predictedwithvariability<20%MildIntermittentSymptoms£295MildPersistentSymptoms>2days/weekbut<1x/daywithnighttimesymptomsgreaterthan2nights/monthExacerbationsmayaffectactivityPeakflow³80%predictedwithvariabilityof<20-30%MildPersistentSymptoms>2da96ModeratePersistentChildislikelytohavedailysymptomsanduserelieverdailyChildiswakingupatleastonceaweekduetoasthmasymptomsPeakflows60-80%ofpredictedwithvariabilityof>30%ActivityisaffectedandexacerbationsmaylastdaysModeratePersistentChildisli97SeverePersistentContinualdaytimesymptomswithfrequentnighttimesymptomsVerylimitedphysicalactivityFrequentexacerbationsPeakflows£60%ofpredictedandvariabilityofmorethan30%TreatmentinvolvesacombinationofmanydrugtherapiesSeverePersistentContinualday98GoalsOfAsthmaTherapyPreventchronicandtroublesomesymptomsMaintain“normal”pulmonaryfunctionMaintainnormalactivitylevels-includingexerciseandotherphysicalactivityMinimizetheneedforemergencyroom/urgentcarevisitsorhospitalizationsGoalsOfAsthmaTherapyPrevent99
GoalsOfAsthmaTherapy
Continued…PreventrecurrentexacerbationsofsymptomsProvideoptimalpharmacotherapywithminimalornoadverseeffectsSatisfythepatient’sandthefamily’sgoalsforasthmacareGoalsOfAsthmaTherapy100
StepwiseApproachTo Asthma TherapyOutcome:BestPossibleResultsReliever:InhaledbetaagonistprnReliever:InhaledbetaagonistprnReliever:InhaledbetaagonistprnReliever:InhaledbetaagonistprnController:OnedailymedicationPossiblyaddlongactingbronchodilatorAnti-leukotrienesController:DailyinhaledcorticosteroidDailylongactingbronchodilatorAnti-leukotrieneController:DailyinhaledcorticosteroidDailylongactingbronchodilatorDaily/alternatedayoralcorticosteroidWhencontrolled,reducetherapyMonitorPEF:≥80%PEF:≥80%PEF:<60%STEP1:IntermittentSTEP2:MildPersistentSTEP3:ModeratePersistentSTEP4:SeverePersistentStepdownOutcome:ControlofAsthmaPEF:60-80% StepwiseApproachToOutcome:101BronchodilatorsRelaxingbronchialsmoothmuscletoopenuptheairway.Anti-inflammatoryagentsInhibitingthedevelopmentofairwayinflammationandstoppingongoinginflammation.Incombination,treatandpreventreversibleairwayobstructionandairwayhyperresponsiveness,relievethesymptomanddecreasetheexacerbation.CommonDrugsforAsthmaBronchodilatorsCommonDrugsfo102Long-termcontrolmedication(Controller)CorticosteriodsCromolyn/nedocromilLongactingb2agonists(LABA)LeukotrienemodifierQuickreliefmedication(Rescuer)Short-actingb2agonistsTheophyllineAnticholinergicsSystemicCorticosteriodsCommonDrugsforAst
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2024-2030年中国海上电站工程行业发展前景及发展策略与投资风险研究报告
- 2024-2030年中国浮动盘管换热器营销策略与投资前景规划研究研究报告
- 2024-2030年中国活性药物成分(API)行业市场发展趋势与前景展望战略分析报告
- 服务业连锁经营模式推广方案
- 2024-2030年中国汽车零配件行业市场发展趋势与前景展望战略分析报告
- 2024-2030年中国汽车转向传动轴行业市场运营模式及未来发展动向预测研究报告
- 2024-2030年中国汽车紧固件行业发展趋势预判及市场前景预测研究报告
- 2024-2030年中国汽车用膜行业市场发展分析及发展趋势与投资前景预测报告
- 2024-2030年中国汽车活塞销行业市场发展趋势与前景展望战略分析报告
- 2024-2030年中国汽车底盘支架行业市场发展趋势与前景展望战略分析报告
- 五年级下册道德与法治第一单元《我们一家人》 单元作业设计
- 小学校本课程-海上“钢铁长城”教学设计学情分析教材分析课后反思
- 《拖地》(教学设计)劳动二年级上册
- 小学语文综合性学习策略研究开题报告
- 前言 马克思主义中国化时代化的历史进程与理论成果
- 甲醛治理投标方案(完整技术标)
- 质量强国建设纲要专题PPT
- 思维导图在高中英语教学中的应用
- 穿行于基础教育森林:教育实践沉思对话录
- 直播营销与运营(微课版)PPT全套完整教学课件
- 英语课题中期报告
评论
0/150
提交评论